My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 129

    1.

    2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies.

    Saven A, Piro LD.

    Ann Intern Med. 1994 May 1;120(9):784-91. Review.PMID: 7908507 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    New prospects in the treatment of indolent lymphomas with purine analogues.

    Cheson BD.

    Cancer J Sci Am. 1998 Jul;4 Suppl 2:S27-36.PMID: 9672772 [PubMed - indexed for MEDLINE]Related articles

    3.

    The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.

    Saven A, Piro LD.

    Cancer. 1993 Dec 1;72(11 Suppl):3470-83. Review.PMID: 7902205 [PubMed - indexed for MEDLINE]Related articles

    4.

    2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.

    Saven A, Piro LD.

    Hematol Cell Ther. 1996 Dec;38 Suppl 2:S93-101. Review.PMID: 9137962 [PubMed - indexed for MEDLINE]Related articles

    5.

    High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.

    Betticher DC, Fey MF, von Rohr A, Tobler A, Jenzer H, Gratwohl A, Lohri A, Pugin P, Hess U, Pagani O, et al.

    Ann Oncol. 1994 Jan;5(1):57-64.PMID: 7909685 [PubMed - indexed for MEDLINE]Related articles

    6.

    Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.

    Tobinai K, Ogura M, Hotta T, Kobayashi Y, Narabayashi M, Suzuki R, Kinoshita T, Kozuru M, Uike N, Ohashi Y.

    Jpn J Clin Oncol. 1997 Jun;27(3):146-53.PMID: 9255268 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders.

    Fidias P, Chabner BA, Grossbard ML.

    Oncologist. 1996;1(3):125-139.PMID: 10387979 [PubMed - as supplied by publisher]Related articlesFree article

    8.

    Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.

    Saven A, Piro LD, Lemon RH, Figueroa ML, Kosty M, Ellison DJ, Beutler E.

    Cancer. 1994 Jun 15;73(12):2953-63.PMID: 7911068 [PubMed - indexed for MEDLINE]Related articles

    9.

    Cladribine in the treatment of chronic lymphocytic leukemia.

    Robak T.

    Leuk Lymphoma. 2001 Feb;40(5-6):551-64. Review.PMID: 11426528 [PubMed - indexed for MEDLINE]Related articles

    10.

    2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.

    O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF.

    Ann Intern Med. 1988 May;108(5):733-43. Review.PMID: 3282467 [PubMed - indexed for MEDLINE]Related articles

    11.

    Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.

    Tobinai K, Uike N, Saburi Y, Chou T, Etoh T, Masuda M, Kawano F, Matsuoka M, Taguchi H, Makino T, Asano Y, Tamura K, Ohashi Y; Cladribine/ATL Study Group, Japan.

    Int J Hematol. 2003 Jun;77(5):512-7.PMID: 12841391 [PubMed - indexed for MEDLINE]Related articles

    12.

    Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.

    Tulpule A, Schiller G, Harvey-Buchanan LA, Lee M, Espina BM, Khan AU, Boswell W, Nathwani B, Levine AM.

    Cancer. 1998 Dec 1;83(11):2370-6.PMID: 9840537 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    New antimetabolites in the treatment of human malignancies.

    Cheson BD.

    Semin Oncol. 1992 Dec;19(6):695-706. Review.PMID: 1361080 [PubMed - indexed for MEDLINE]Related articles

    14.

    2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.

    Saven A, Piro LD.

    Leuk Lymphoma. 1993;10 Suppl:43-9. Review. No abstract available. PMID: 8097654 [PubMed - indexed for MEDLINE]Related articles

    15.

    Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia.

    Saven A, Lee T, Schlutz M, Jacobs A, Ellison D, Longmire R, Piro L.

    J Clin Oncol. 1997 Jan;15(1):37-43.PMID: 8996122 [PubMed - indexed for MEDLINE]Related articles

    16.

    Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.

    Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ.

    Cancer. 2006 Oct 1;107(7):1542-50.PMID: 16948126 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    [Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)]

    Góra-Tybor J, Robak T.

    Przegl Lek. 1996;53(8):614-8. Review. Polish. PMID: 8999463 [PubMed - indexed for MEDLINE]Related articles

    18.

    Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.

    Robak T, Korycka A, Robak E.

    Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):23-38. Review.PMID: 18221024 [PubMed - indexed for MEDLINE]Related articles

    19.

    [Cladribine]

    Ogura M.

    Gan To Kagaku Ryoho. 2003 Feb;30(2):309-17. Review. Japanese. PMID: 12610885 [PubMed - indexed for MEDLINE]Related articles

    20.

    Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

    Robak T, Lech-Maranda E, Korycka A, Robak E.

    Curr Med Chem. 2006;13(26):3165-89.PMID: 17168705 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity